Date Added: 20/03/2017

Date Updated: 20/03/2017

Apalutamide for pre-metastatic hormone-refractory prostate cancer — add-on and substitute therapy

Specialties: Oncology & radiotherapy

Technology Type: Drugs

Stage of development: Investigational - phase III

Stage of EAA: Prioritised for assessment

Description, patients and keywords:

Indication:

Prostate cancer.

Subgroup

Hormone-refractory (also termed castration resistant).

Stage of disease

Pre-metastatic, chemotherapy naïve.

Place in Treatment

Add-on and substitute.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.